The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity for a period of six months. This exclusivity is in addition to any existing patent or market exclusivity for a drug. It is awarded when a drug manufacturer conducts clinical trials in children as part of a written request from the FDA. [1]
When Does Pediatric Exclusivity Apply?
Pediatric exclusivity is granted when a sponsor agrees to conduct clinical trials in the pediatric population in response to an FDA written request. This request may cover new uses of a drug, new formulations, or new dosages for children. [1]
How Does Pediatric Exclusivity Affect Patent Expiration?
Pediatric exclusivity extends the period during which a drug is protected from generic competition. If a drug has an existing patent or market exclusivity, the six-month pediatric exclusivity is added to the end of that period. This effectively delays the entry of generic versions of the drug into the market. [1]
What is the Goal of Pediatric Exclusivity?
The primary goal of the Best Pharmaceuticals for Children Act (BPCA), which established pediatric exclusivity, is to encourage pharmaceutical companies to conduct necessary studies to gather data on the safe and effective use of drugs in children. Before the BPCA, many drugs were prescribed to children without adequate clinical trials, leading to off-label use and potential safety concerns. [1]
How Does Pediatric Exclusivity Differ from Other Exclusivities?
Unlike patent protection, which is granted by the U.S. Patent and Trademark Office (USPTO) for a period of typically 20 years from the filing date, pediatric exclusivity is a regulatory incentive granted by the FDA. It is a fixed six-month extension. Market exclusivity, such as New Chemical Entity (NCE) exclusivity (five years) or orphan drug exclusivity (seven years), is also granted by the FDA based on specific criteria, but pediatric exclusivity is solely tied to conducting pediatric studies. [1]
Can Generic Companies Challenge Pediatric Exclusivity?
While pediatric exclusivity is a regulatory grant, the underlying patents or market exclusivities associated with a drug can be challenged by generic manufacturers. If a patent or market exclusivity is invalidated or expires, generic companies may attempt to enter the market, even if pediatric exclusivity is still in effect. However, the FDA will not approve a generic application for six months after the expiration of the last-to-expire patent or market exclusivity, whichever provides the later date, if pediatric exclusivity has been granted. [1]
Where Can I Find More Information on Drug Patents and Exclusivity?
For detailed information on drug patents, exclusivity periods, and potential market entry dates for generic drugs, resources like DrugPatentWatch.com are valuable. This platform tracks patent information and provides insights into the exclusivity status of various pharmaceuticals. [2]
Sources
1. U.S. Food and Drug Administration
2. DrugPatentWatch.com